【摘要】：目的探討干擾素(IFN)β-1b用于治療中國東北地區(qū)復(fù)發(fā)緩解型多發(fā)性硬化(RRMS)患者的臨床療效。方法對21例確診的RRMS患者給予皮下注射IFNβ-1b治療并隨訪1年,觀察患者擴展的殘疾狀況評分(EDSS)、頭顱磁共振成像(MRI)T2加權(quán)像病灶及Gd-DTPA強化病灶數(shù)量、漢密爾頓抑郁量表(HAMD)評分、EDSS評分與專用生活質(zhì)量(MSQOL-54)量表評分相關(guān)性及使用IFNβ-1b前后的年復(fù)發(fā)次數(shù),同時觀察藥物不良反應(yīng)。結(jié)果 21例患者治療1年前后神經(jīng)功能障礙改善,EDSS評分比較差異顯著(P0.05);MS患者治療前后EDSS評分與生活質(zhì)量呈負相關(guān)(r=-0.808,0.755),生活質(zhì)量有一定改善;頭顱MRI新增的T2上及Gd強化病灶數(shù)較治療前減少(P0.05);應(yīng)用IFNβ-1b 1年前后復(fù)發(fā)的次數(shù),差異有統(tǒng)計學意義(P0.005);治療1年前后HAMD評分比較差異無統(tǒng)計學意義(P=0.171)。結(jié)論 IFNβ-1b對于RRMS有較好的療效,延緩臨床神經(jīng)功能障礙程度,改善生活質(zhì)量,降低復(fù)發(fā),減少顱內(nèi)新發(fā)病灶數(shù)目,未明顯加重抑郁狀態(tài);副作用多為應(yīng)用初期一過性且可耐受。
[Abstract]:Objective to investigate the clinical efficacy of interferon (IFN) 尾-1b in the treatment of recurrent and remission multiple sclerosis (RRMS) patients in Northeast China. Methods Twenty-one patients with RRMS were treated with subcutaneous injection of IFN 尾 -1b and followed up for one year. The number of (MRI) T2-weighted lesions and Gd-DTPA enhanced lesions in (EDSS), head magnetic resonance imaging (EDSS),) were observed. The (HAMD) score, EDSS score and MSQOL-54 score of Hamilton Depression scale were correlated with the number of annual recurrence before and after IFN 尾 -1b use, and the adverse drug reactions were observed at the same time. Results the neurological dysfunction was improved in 21 patients before and after one year treatment, and the difference of EDSS score was significant (P0.05). The EDSS score was negatively correlated with the quality of life (r = 0.808, 0.755), and the quality of life was improved to some extent. The number of enhanced lesions on T2 and Gd increased by MRI was lower than that before treatment (P0.05), and the number of recurrence before and after 1 year of IFN 尾 -1b was significantly different (P0.005). There was no significant difference in HAMD score before and after treatment (P < 0. 171). Conclusion IFN 尾 -1b has a good effect on RRMS, delaying the degree of clinical neurological dysfunction, improving the quality of life, reducing the recurrence, reducing the number of new intracranial lesions, and not exacerbating the depression state. The side effects were transient and tolerable in the early stage of application.
【作者單位】： 吉林大學中日聯(lián)誼醫(yī)院神經(jīng)內(nèi)一科;吉林大學中日聯(lián)誼醫(yī)院放射線科;邯鄲市第一醫(yī)院神經(jīng)內(nèi)科;
【基金】：吉林省科技發(fā)展計劃國際科技合作項目(20110719)
【分類號】：R744.51

【相似文獻】

相關(guān)期刊論文 前1條

1 張紅;高血壓伴糖尿病致腔隙性腦梗死臨床研究[J];四川醫(yī)學;2005年10期

，

本文編號：2369808